Daniel Shepshelovich

Daniel Shepshelovich

Auto-generated profile, based on publicly available information

Daniel Shepshelovich

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
DSDaniel Shepshelovich
Daniel Shepshelovich
BRBenaya Rozen-Zvi
Benaya Rozen-Zvi
TATomer Avni
Tomer Avni
UGUzi Gafter
Uzi Gafter
AGAnat Gafter-Gvili
Anat Gafter-Gvili

25 January 2024 in Drug Safety
Verified
Journal Article
Open access
PDF file
BCBronya Calvarysky
Bronya Calvarysky
IDIdit Dotan
Idit Dotan
DSDaniel Shepshelovich
Daniel Shepshelovich
ALAvi Leader
Avi Leader
TCTalia Diker Cohen
Talia Diker Cohen
Background Glucagon-like peptide 1 receptor agonists (GLP1RAs) are used in the treatment of diabetes and obesity. Their slowing effect of gastric emptying might change oral drug absorption, potentially affecting pharmacokinetics, particularly in the case of medications with a narrow therapeutic index. Purpose The purpose of this systematic review is to summarize data on drug-drug interactions between GLP1RAs and oral drugs. Data Sources The PubMed and EMBASE databases were searched up to November, 1st 2023. Study Selection We selected pharmacokinetic studies of any injectable GLP1RA given with an oral medication, and product prescribing sheets reporting data without access to the original study. Data Extraction Two authors independently extracted the data. Data Synthesis Twenty-two reports and six prescribing sheets were included. Treatment with GLP1RAs resulted in unaffected or reduced Cmax and delayed tmax of drugs with high solubility and permeability (warfarin, contraceptive pills, acetaminophen), drugs with high solubility and low permeability (angiotensin converting enzyme inhibitors), drugs with low solubility and high permeability (statins) and drugs with low solubility and permeability (digoxin). However, the use of GLP1RAs did not exert clinically significant changes in the AUC or differences in clinically relevant endpoints. Limitations The major limitations of the studies that are included in this systematic review are the enrollment of healthy subjects and insufficient data in conditions that might affect pharmacokinetics (e.g., kidney dysfunction). Conclusions To conclude, reduced Cmax and delayed tmax of drugs co-administered with GLP1RAs are consistent with the known delayed gastric output by the latter. Nevertheless, the overall drug exposure was not considered clinically significant. Dose adjustments are probably not required for simultaneous use of GLP1RAs with oral medications. Still, results should be carefully generalized to cases of background kidney dysfunction or when using drugs with narrow therapeutic index. The study is registered in PROSPERO: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022332339.

2 March 2017 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
DSDaniel Shepshelovich
Daniel Shepshelovich
ASAmir Schechter
Amir Schechter
BCBronislava Calvarysky
Bronislava Calvarysky
TDTalia Diker‐Cohen
Talia Diker‐Cohen
BRBenaya Rozen‐Zvi
Benaya Rozen‐Zvi
AGAnat Gafter‐Gvili
Anat Gafter‐Gvili

13 February 2019 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
ASAmir Schechter
Amir Schechter
AGAnat Gafter-Gvili
Anat Gafter-Gvili
DSDaniel Shepshelovich
Daniel Shepshelovich
RRRuth Rahamimov
Ruth Rahamimov
UGUzi Gafter
Uzi Gafter
BRBenaya Rozen-Zvi
Benaya Rozen-Zvi
Post transplantation anemia (PTA) is common among kidney transplant patients. PTA is associated with increased graft loss and in most studies with increased mortality. However, the effect of the severity of anemia on this associations was not thoroughly evaluated. Patients who underwent kidney transplantation in Rabin Medical Center (RMC) were included in the study. Data were collected during the years 2002–2016. Anemia was defined as hemoglobin (Hb) level less than 12 g/dL in women and less than 13 g/dL in men, in accordance with World Health Organization (WHO) criteria. Severe anemia was defined as hemoglobin lower than 11 g/dL. Primary outcome was a composite of patient and graft survival. We used univariate and multivariate models to evaluate association between severity and specific causes of anemia with the outcomes. As the risk associated with anemia changed over time we analyzed the risk separately for the early and the late period (before and after 1251 days). Our cohort included 1139 patients, 412 (36.2%) of which had PTA and 134 (11.7%) had severe anemia. On multivariable analysis, severe anemia was highly associated with the primary outcome at the early period (HR 6.26, 95% CI 3.74–10.5, p < 0.001). Anemia due to either AKI & acute rejection (11.9% of patients) or infection (16.7%), were associated with primary outcome at the early period (HR 9.32, 95% CI 5.3–26.41, p < 0.001 and HR 3.99, 95% CI 2.01–7.95, p < 0.001, respectively). There was non-significant trend for association between anemia due to Nutritional deficiencies (29.1%) and this outcome (HR 3.07, 95% CI 0.93–10.17, p = 0.067). PTA is associated with graft loss and mortality especially during the first three years. Anemia severity affects this association. An anemia workup is recommended for PTA.

22 February 2021 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
ZVZachary Veitch
Zachary Veitch
DSDaniel Shepshelovich
Daniel Shepshelovich
CGChristina Gallagher
Christina Gallagher
LWLisa Wang
Lisa Wang
ARAlbiruni R Abdul Razak
Albiruni R Abdul Razak
AHAaron R. Hansen
Aaron R. Hansen
Background: Clinician reporting of symptomatic adverse events (AEs) in phase I trials uses the Common Terminology Criteria for Adverse Events (CTCAE). The utility of the patient-reported outcomes (PROs) version of the CTCAE (PRO-CTCAE) in this setting is unknown. This prospective, observational study compared patient- and clinician-reported symptomatic AEs in phase I patients. Methods: Phase I study–eligible patients at Princess Margaret were surveyed with the PRO-CTCAE full-item library (78 symptomatic AEs) at baseline (BL), mid-cycle 1, and mid-cycle 2 (C2). Patient and trial characteristics, best response, and survival data were collected. Presence or absence of patient- (PRO-CTCAE) or clinician-reported symptomatic AEs were compared (kappa) at defined timepoints and overall (BL+ mid-cycle 1 + C2). Results: Of 292 patients approached from May 2017 to January 2019, a total of 265 (90.8%) were consented, with 243 (91.7%) evaluable and 552 PRO-CTCAE surveys (completion rate = 98.7%) included in analyses. Evaluation of overall patient-reported symptomatic AEs identified 50 PRO-CTCAE and 11 CTCAE items with 10% or greater reporting frequency. Nineteen CTCAE items were reported as 1% or less despite matched PRO-CTCAE items reporting as 10% or greater. Underreported categories included sexual health, bodily emissions, and cognition. Clinician- relative to patient-reporting frequency (ratio) demonstrated 9 symptomatic AEs with a 50-fold or more lower clinician reporting rate. Overall patient–clinician agreement for individual symptomatic AEs ranged from poor (κ = 0.00-0.19) to moderate (κ = 0.40-0.59), with discordance driven by lack of clinician reporting. Dyspnea (κ = 0.54) and peripheral neuropathy (κ = 0.63) at BL and limb edema (κ = 0.55) at C2 demonstrated the highest patient–clinician agreement. Conclusions: Poor to moderate patient–clinician agreement for symptomatic AEs suggests clinician underreporting in phase I trials. Analyses of severity and interference PRO categories are ongoing.

1 December 2015 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
DSDaniel Shepshelovich
Daniel Shepshelovich
CLChiya Leibovitch
Chiya Leibovitch
AKAlina Klein
Alina Klein
SZShirit Zoldan
Shirit Zoldan
GMGai Milo
Gai Milo
MLMeir Lahav
Meir Lahav